Reckitt Benckiser's $1.4bn settlement over Suboxone verges on the farcical | Nils Pratley

The UK company may have avoided a day in court, but its claims of innocence will never be testedOne can say it is entirely logical for the board of Reckitt Benckiser to write a cheque for $1.4bn (£1.1bn) to end US authorities’ investigation into how opioid treatment Suboxone Film was marketed by a former subsidiary. One can also call the outcome ridiculous.The logical aspect lies in the commercial opportunity to make a serious legal headache go away with no admission of wrongful conduct. Fighting the US Department of Justice (DoJ) and Federal Trade Commission (FTC) in front of a jury would be a high-risk strategy for a UK company, especially against the backdrop of an opioid crisis in the US that has claimed 200,000 lives. The detail that Suboxone was meant to be treating addiction could become lost in the anger. Continue reading…

Read More